English
Specials
    Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsBusinessStocksSun Pharma surges after April-June results

    Sun Pharma surges after April-June results

    Sun, India's top drugmaker by market value, reported on Friday a net loss of Rs 1276 crore for the June quarter, due to a provisioning charge to settle a patent suit

    May 02, 2019 / 13:03 IST
       
       
      26 Aug, 2025 12:21
      Volume
      Todays L/H
      More

      Sun Pharmaceutical Industries shares surged as much as 9 percent on Monday after the drugmaker's April-June earnings were seen as positive after factoring out a provisioning charge to settle a patent suit.


      Sun, India's top drugmaker by market value, reported on Friday a net loss of Rs 1276 crore for the June quarter, due to the provision.

      Also Read: Sun Pharma posts Rs 1276 cr loss in Q1 on Pfizer settlement


      Profit adjusted after the provision came in at Rs 1240 crore, analysts said.


      Sun Pharma, along with Teva Pharmaceuticals Industries, has to pay Pfizer Inc USD 2.15 billion to settle a patent suit related to marketing generic versions of its acid-reflux drug Protonix.


      Sun shares were up nearly 9 percent at 9.48 AM, outperforming a 0.05 percent gain in the broader Nifty.

      first published: Aug 12, 2013 10:30 am

      Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

      Subscribe to Tech Newsletters

      • On Saturdays

        Find the best of Al News in one place, specially curated for you every weekend.

      • Daily-Weekdays

        Stay on top of the latest tech trends and biggest startup news.

      Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347